Clinical trials: Vaccinations
Smallpox
MVA Post-Event: Administration Timing and Boost Study
The purpose of this study is to evaluate an investigational smallpox vaccine, called IMVAMUNE®, with respect to safety and immune (body's defense system) response.
- Trial name
- NCT00437021
- Testing
- Live vaccinia virus vaccine, MVA Smallpox Vaccine
- Where
- 7 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaccination Refusal
Group Intervention on Vaccine Confidence
This study has one primary objective and two secondary objectives, with an overall goal of understanding barriers to vaccination and vaccination confidence, so that effective interventional strategies can be further developed and…
- Trial name
- NCT05891626
- Testing
- Group intervention
- Where
- United States
- Volunteers
- 429 people, healthy volunteers welcome
- Sponsor
- MultiCare Health System Research Institute
Parkinson's Disease
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.
An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
- Trial name
- NCT07777484
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Tridem Bioscience FlexCo
Vaccination Refusal
An Adaptive Prenatal Intervention to Increase Childhood Vaccinations
This study will test whether proactively connecting expectant parents with factual vaccination information during pregnancy can build confidence in vaccinations and lead to timely vaccinations during pregnancy and once their…
- Trial name
- ADEPT (NCT05795855)
- Testing
- ADEPT
- Where
- United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Emory University
Haemophilus Influenzae Type b, Neisseria Meningitidis
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine compared to 2 control groups receiving licensed meningococcal serogroup C conjugate vaccine and/or licensed Hib conjugate vaccine…
- Trial name
- NCT00127855
- Testing
- Hib-MenCY-TT vaccine (MenHibrix), Meningitec®, ActHIB®
- Where
- 3 sites in Australia
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
HPV Vaccination in Women With Cystic Fibrosis
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19…
- Trial name
- VACCIN-HPV-MUC (NCT03265743)
- Testing
- Self-report Written Questionnaire
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Hospices Civils de Lyon
Hematologic Malignancy, Pediatric Cancer
Response to Influenza Vaccination in Pediatric Oncology Patients
Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity in the form of lower respiratory tract infection (LRTI) and mortality…
- Conditions
- Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
- Trial name
- NCT05384288
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. Jude Children's Research Hospital
Improve Childhood Immunization Rates
Improving Childhood Immunization
Specific Aim: To improve childhood immunization rates by utilizing automated Electronic Health Record-derived provider-specific performance feedback reports, coupled with automated Electronic Health Record-derived trigger alerts.
- Trial name
- ImmProve (NCT01794286)
- Testing
- Provider bulletins, Trigger alerts
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Johns Hopkins University
Immunization; Infection
Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study
This study aims to implement and test the efficacy of photovoice, Short Messaging Service (SMS) and phone call reminders in improving childhood immunization coverage (uptake, timeliness and completion rates) and reducing…
- Trial name
- MOPING (NCT03402646)
- Testing
- Reminder module (SMS and Phone call), Photovoice
- Volunteers
- 1,813 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
Gonorrhoea
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae…
- Trial name
- NCT04722003
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningococcal Immunization, Healthy Volunteers
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa
This will be a Phase III, modified double-blind (open-label for toddlers in India), randomized, parallel-group, active-controlled, step-wise, multi-center study to compare and describe the immunogenicity and safety of MenACYW…
- Trial name
- MET55 (NCT04143061)
- Testing
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine
- Where
- 17 sites in India, South Africa
- Volunteers
- 1,328 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HPV
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children…
- Trial name
- NCT04722822
- Testing
- (Intervention) Recommending HPV vaccine for patients 9-10 years of age, (Control) Recommending HPV vaccine for patients 11-12 years of age
- Where
- 2 sites in United States
- Volunteers
- 62,272 people
- Sponsor
- University of Colorado, Denver
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Giant Cell Glioblastoma, Glioblastoma
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01957956
- Testing
- Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Autoimmune State, SARS-CoV-2 Infection
Security Efficacy COVID-19 Vaccination
Preliminary data support a possible molecular mimicry between SARS-CoV-2 and autologous components. This suggests the occurrence of autoimmunity during COVID-19. Consistently, autoimmunity may occur after SARS-CoV2 vaccination.
- Trial name
- SECVAX (NCT05743361)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
PNC Vaccine, HIV-infected Pregnant Women
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
The purpose of this study was to determine the safety, reactogenicity, immunogenicity, transplacental antibody transfer and interference with infant responses to childhood vaccination of maternal vaccination with pneumococcal…
- Trial name
- NCT02717494
- Testing
- PPV-23, PCV-10, NaCl
- Where
- 8 sites in Brazil
- Volunteers
- 347 people
- Sponsor
- Westat
Preference, Patient
Preferences of Vaccination for COVID-19 Among University Students and Staff: A Discrete Choice Experiment
From March 2021, COVID-19 vaccines have been made available to Hong Kong residents, first to priority groups including healthcare professionals and the elderly, and later to all adults and adolescents.
- Trial name
- NCT05150769
- Where
- Hong Kong
- Volunteers
- 3,423 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Vitamin d Deficiency, COVID-19
Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl
The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of: occurence of Long COVID syndrome after acute COVID-19 illness occurence of SARS-CoV-2…
- Conditions
- Vitamin d Deficiency, COVID-19, Long COVID
- Trial name
- LONGVITAVAX2 (NCT06452082)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Cervical Intraepithelial Neoplasia (CIN), Genital Warts
Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment
The goal of this observational study is to assess the impact of HPV vaccination on cervical lesions and genital warts in Colombian birth cohorts.
- Conditions
- Cervical Intraepithelial Neoplasia (CIN), Genital Warts, Papillomavirus Infections, Cervical Cancers
- Trial name
- NCT06700941
- Testing
- HPV vaccine
- Where
- Colombia
- Volunteers
- 8,000,000 people
- Sponsor
- Universidad Nacional de Colombia
Malignant Glioma
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 24 months.
- Trial name
- NCT01792505
- Testing
- Dendritic Cell Vaccine in combination with Imiquimod cream
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Cedars-Sinai Medical Center